drugset
drugset / Trial / NCT00405067

The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia

NCT00405067 ↗

Phase 2 Completed 60 enrolled Aegerion Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The main objectives of this study are to evaluate the efficacy and safety of combination therapy BMS-201038 (AEGR-733) plus ezetimibe vs. each agent given alone on LDL cholesterol and other lipoproteins over 12 weeks of therapy.

Timeline

Start
2006-05
Primary completion
2007-01
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg —
Subject lomitapide Small molecule 10 mg —

Indications

hyperlipidemia